Improving the performance of factor VIII inhibitor tests in hemophilia A.
作者信息
Miller Connie H
机构信息
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, MS D-02, Atlanta, GA 30333 USA.
出版信息
Thromb Res. 2015 Dec;136(6):1047-8. doi: 10.1016/j.thromres.2015.09.019. Epub 2015 Sep 28.
Abstract
摘要
相似文献
1
Improving the performance of factor VIII inhibitor tests in hemophilia A.
Thromb Res. 2015 Dec;136(6):1047-8. doi: 10.1016/j.thromres.2015.09.019. Epub 2015 Sep 28.
2
Correlation between factor VIII genotype and inhibitor development in hemophilia A.
Semin Thromb Hemost. 2000;26(2):167-71. doi: 10.1055/s-2000-9819.
3
Hemodialysis in a patient with severe hemophilia A and factor VIII inhibitor.
Hemodial Int. 2016 Oct;20(4):E11-E13. doi: 10.1111/hdi.12429. Epub 2016 May 5.
4
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ. 1995 Jul 15;153(2):147-57.
5
6
Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:106-12.
7
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
J Thromb Haemost. 2017 Jul;15(7):1422-1429. doi: 10.1111/jth.13711. Epub 2017 Jun 2.
8
Successful peritoneal dialysis in a hemophilia A patient with factor VIII inhibitor.
Perit Dial Int. 2010 Jan-Feb;30(1):114-6. doi: 10.3747/pdi.2009.00011.
9
Acquired Hemophilia A: A Case Report.
J Pharm Pract. 2020 Aug;33(4):562-566. doi: 10.1177/0897190019826474. Epub 2019 Feb 6.
10
Inhibitor antibodies to factor VIII and factor IX: management.
Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821.
引用本文的文献
1
European principles of inhibitor management in patients with haemophilia.
Orphanet J Rare Dis. 2018 Apr 27;13(1):66. doi: 10.1186/s13023-018-0800-z.
本文引用的文献
1
Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction.
Thromb Res. 2015 Dec;136(6):1280-4. doi: 10.1016/j.thromres.2015.08.014. Epub 2015 Aug 28.
2
The EPIC study: a lesson to learn.
Haemophilia. 2015 Sep;21(5):622-8. doi: 10.1111/hae.12666. Epub 2015 Apr 23.
3
A public health approach to the prevention of inhibitors in hemophilia.
Am J Prev Med. 2014 Nov;47(5):669-73. doi: 10.1016/j.amepre.2014.07.007. Epub 2014 Sep 19.
4
Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A.
Br J Haematol. 2014 Sep;166(6):953-6. doi: 10.1111/bjh.12923. Epub 2014 May 9.
5
Laboratory testing for factor inhibitors.
Haemophilia. 2014 May;20 Suppl 4:94-8. doi: 10.1111/hae.12408.
6
A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302. Epub 2013 Nov 22.
7
Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.
8
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
9
Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.
J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.
10
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.
Blood. 2011 Jun 9;117(23):6367-70. doi: 10.1182/blood-2010-09-308668. Epub 2011 Apr 6.
Zotero 插件